JAK3, STAT3 and CD3-zeta signaling proteins status in regard to the lymphocytes function in patients with ovarian cancer.
about
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.Gamma-aminobutyric acid binds to GABAb receptor to inhibit cholangiocarcinoma cells growth via the JAK/STAT3 pathway.Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
P2860
JAK3, STAT3 and CD3-zeta signaling proteins status in regard to the lymphocytes function in patients with ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
JAK3, STAT3 and CD3-zeta signa ...... patients with ovarian cancer.
@en
JAK3, STAT3 and CD3-zeta signa ...... patients with ovarian cancer.
@nl
type
label
JAK3, STAT3 and CD3-zeta signa ...... patients with ovarian cancer.
@en
JAK3, STAT3 and CD3-zeta signa ...... patients with ovarian cancer.
@nl
prefLabel
JAK3, STAT3 and CD3-zeta signa ...... patients with ovarian cancer.
@en
JAK3, STAT3 and CD3-zeta signa ...... patients with ovarian cancer.
@nl
P2093
P2860
P1476
JAK3, STAT3 and CD3-zeta signa ...... patients with ovarian cancer.
@en
P2093
Katarzyna Bednarska
Marek Nowak
Zofia Sulowska
P2860
P304
P356
10.3109/08820139.2011.640376
P577
2012-01-05T00:00:00Z